A Phase 2, Open-label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in Combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
October 25, 2018
End Date
October 17, 2023
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
October 25, 2018
End Date
October 17, 2023